Abstract
Background: Preterm birth (PTB), or birth that occurs before 37 weeks of gestation, accounts for the majority of perinatal morbidity and mortality. As of 2016, PTB has an occurrence rate of 9.6% in the United States and accounts for up to 18 percent of births worldwide. Inflammation has been identified as the most common cause of PTB, but effective pharmacotherapy has yet to be developed to prevent inflammation driven PTB. Our group has discovered that N,N-dimethylacetamide (DMA), a readily available solvent commonly used as a pharmaceutical excipient, rescues lipopolysaccharide (LPS)-induced timed pregnant mice from PTB.
Methods: We have used in vivo, ex vivo and in vitro approaches to investigate this compound further.
Results: Interestingly, we found that DMA suppresses cytokine secretion by inhibiting nuclear factor-kappa B (NF-κB). In ongoing work in this exciting line of investigation, we are currently investigating structural analogs of DMA, some of them novel, to optimize this approach focused on the inflammation associated with PTB.
Conclusion: Successful development of pharmacotherapy for the prevention of PTB rests upon the pursuit of multiple strategies to solve this important clinical challenge.
Keywords: Gestation, inflammation, lipopolysaccharide, N, N-dimethylacetamide, nuclear factor kappa B, preterm birth.
Current Pharmaceutical Design
Title:Repurposing N,N-Dimethylacetamide (DMA), a Pharmaceutical Excipient, as a Prototype Novel Anti-inflammatory Agent for the Prevention and/or Treatment of Preterm Birth
Volume: 24 Issue: 9
Author(s): Samir Gorasiya*, Juliet Mushi, Ryan Pekson, Sabesan Yoganathan and Sandra E. Reznik
Affiliation:
- Department of Pharmaceutical Sciences College of Pharmacy and Health Sciences St. John`s University, Queens, NY 11439,United States
Keywords: Gestation, inflammation, lipopolysaccharide, N, N-dimethylacetamide, nuclear factor kappa B, preterm birth.
Abstract: Background: Preterm birth (PTB), or birth that occurs before 37 weeks of gestation, accounts for the majority of perinatal morbidity and mortality. As of 2016, PTB has an occurrence rate of 9.6% in the United States and accounts for up to 18 percent of births worldwide. Inflammation has been identified as the most common cause of PTB, but effective pharmacotherapy has yet to be developed to prevent inflammation driven PTB. Our group has discovered that N,N-dimethylacetamide (DMA), a readily available solvent commonly used as a pharmaceutical excipient, rescues lipopolysaccharide (LPS)-induced timed pregnant mice from PTB.
Methods: We have used in vivo, ex vivo and in vitro approaches to investigate this compound further.
Results: Interestingly, we found that DMA suppresses cytokine secretion by inhibiting nuclear factor-kappa B (NF-κB). In ongoing work in this exciting line of investigation, we are currently investigating structural analogs of DMA, some of them novel, to optimize this approach focused on the inflammation associated with PTB.
Conclusion: Successful development of pharmacotherapy for the prevention of PTB rests upon the pursuit of multiple strategies to solve this important clinical challenge.
Export Options
About this article
Cite this article as:
Gorasiya Samir *, Mushi Juliet , Pekson Ryan , Yoganathan Sabesan and Reznik E. Sandra , Repurposing N,N-Dimethylacetamide (DMA), a Pharmaceutical Excipient, as a Prototype Novel Anti-inflammatory Agent for the Prevention and/or Treatment of Preterm Birth, Current Pharmaceutical Design 2018; 24 (9) . https://dx.doi.org/10.2174/1381612824666180130121706
DOI https://dx.doi.org/10.2174/1381612824666180130121706 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Catecholamines in Formation and Resolution of Pulmonary Oedema
Cardiovascular & Hematological Disorders-Drug Targets Preface
Current Tissue Engineering (Discontinued) The Future of Diabetes Management by Healthy Probiotic Microorganisms
Current Diabetes Reviews Beyond Lipoprotein Receptors: Learning from Receptor Knockouts Mouse Models about New Targets for Reduction of the Atherosclerotic Plaque.
Current Molecular Medicine The Lord of the Bacteria: The Fellowship of the Leader and Other Serine Protease Inhibitors
Current Pharmaceutical Design EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets Molecular Mechanism of Anti-tumor Effect by Triptolide in Hematological Malignancies
Current Signal Transduction Therapy New Insights into Invasive Aspergillosis - from the Pathogen to the Disease
Current Pharmaceutical Design Pomegranate as a Possible Treatment in Reducing Risk of Developing Wound Healing, Obesity, Neurodegenerative Disorders, and Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Animal Models of Maternal Immune Activation in Depression Research
Current Neuropharmacology Skin Tests in the Diagnosis of Drug Hypersensitivity Reactions
Current Pharmaceutical Design IL-6 and Crohns Disease
Current Drug Targets - Inflammation & Allergy Pleiotropic Roles of Runx Transcription Factors in the Differentiation and Function of T Lymphocytes
Current Immunology Reviews (Discontinued) Meet Our Editorial Board Member
Recent Patents on Inflammation & Allergy Drug Discovery Selective Serotonin-norepinephrine Re-uptake Inhibition Limits Renovas-cular-hypertension Induced Cognitive Impairment, Endothelial Dysfunction, and Oxidative Stress Injury
Current Neurovascular Research Artificial Carriers: A Strategy for Constructing Antigenic/Immunogenic Conjugates
Current Topics in Medicinal Chemistry Alcohol Abuse, Immunosuppression, and Pulmonary Infection
Current Drug Abuse Reviews TXNL1 Induces Apoptosis in Cisplatin Resistant Human Gastric Cancer Cell Lines
Current Cancer Drug Targets Micronutrient Intake in the Etiology, Prevention and Treatment of Osteosarcopenic Obesity
Current Aging Science Visceral Adiposity Measurements, Metabolic and Inflammatory Profi le in Obese Patients with and Without Type 2 Diabetes Mellitus: A Crosssectional Analysis
Current Diabetes Reviews